Press "Enter" to skip to content

New patent expiration for Septodont Holding drug ORAVERSE

0
Copyright © DrugPatentWatch. Originally published at New patent expiration for Septodont Holding drug ORAVERSE

Annual Drug Patent Expirations for ORAVERSE
Annual Drug Patent Expirations for ORAVERSE

Oraverse is a drug marketed by Septodont Holding and is included in one NDA. It is available from one supplier. There are five patents protecting this drug.

This drug has thirty-one patent family members in twenty countries.

The generic ingredient in ORAVERSE is phentolamine mesylate. One supplier is listed for this compound. Additional details are available on the phentolamine mesylate profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at New patent expiration for Septodont Holding drug ORAVERSE
Online Certificate Course

Decision-Making for Generic Drug Entry & Branded Drug Lifecycle Management

  • When will key drug patents expire?
  • How can I find, evaluate, and plan for generic market entry opportunities?
  • How can I find proprietary out-of-court settlements and deal terms?
DrugPatentWatch - Make Better Decisions